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Abstract
Objective: The objective of this study was to determine the morphologic spectrum and risk category of gastrointestinal 
stromal tumour (GIST) and compare with overall patient survival.
Materials and Methods: It is a descriptive observational study. The study was carried at Shifa International Hospital, 
Islamabad. Duration of the study was from January 2009 to January 2015. A total of 31 patients with the diagnosis of 
GIST were included, irrespective of age and gender. Data were retrieved from laboratory information system. Results 
were analysed by statistical software, Statistical Package of the Social Sciences. Morphologic type, site of tumour, 
risk category and overall survival were determined and mean, standard deviation, frequencies and percentages were 
calculated for age site and risk category.
Results: Of 31 patients, 21 (67.7%) were male and 10 (32.3%) were female. Site of tumour was as follows: Gastric 13 (41.9%), 
extra visceral 6 (19.4%), small intestine 9 (29.0%), rectum 2 (6.5%) and pancreas 1 (3.2%). According to risk categorisation, 
one was categorised as (3.2%) very low risk, 3 (9.7%) low risk, 5 (16.1%) intermediate risk and 22 (71%) high risk. Follow-up 
was available in 21 patients. 7 patients (22.5%) lost to follow-up. 8 (25%) had recurrence and 4 (12.9%) died.
Conclusion: Majority of cases diagnosed at our centre were gastric in origin followed by small intestine, and as per 
risk categorisation, most were high risk. Patient survival with high-risk tumours was dismal.
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Introduction
Gastrointestinal stromal tumours (GISTs) were initially 
believed to be of smooth muscle origin.[1] However, 
now, this theory has been replaced by the fact that these 
originate from cells of Cajal, the pacemakers of gut.[2] 
Many population-based studies in Western countries have 
been published regarding epidemiology and prognosis 
of GISTs. However, there are few studies available in 
literature to document the characteristics of GISTs in 
Asian countries, especially in Pakistan.[3]
GIST-affected patients have vague symptoms and 
mostly are discovered incidentally.[1,3,4] Most GISTs arise 
sporadically, but a small proportion arises with other 
tumours, (Carney triad) familial GIST syndrome and 
neurofibromatosis type 1 (NF1).[4]
Stomach is the most common site of GIST (approximately 
60–70%). Followed by small intestine (20–30%), while 
<10% arise from oesophagus, colon, rectum, omentum 
and mesentery. Around 10–30% of GISTs fall in high-risk 
category. Omentum/peritoneum and liver are the most 
common sites of recurrence and metastasis.[2]
The diagnosis of GIST is made on typical histologic features; 
however, it has to be confirmed by immunohistochemical 
(IHC) panel including CD117 (c-kinase receptor [Kit]) 
and diagnosed on GIST (DOG1). CD 117 positivity 
is important for diagnosis of GIST as well as for 
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therapeutic reasons. Up to 95% are positive for CD117.[2] 
About 70% of GIST are positive for CD34. The current 
recommendation by the College of American Pathologists 
cancer protocols, regarding the behaviour of GIST, is their 
stratification into very low, low, intermediate, high and 
very high-risk groups. This grouping is based on assessing 
location of tumour, gross tumour size as well as mitotic 
count in 20 high-power fields (HPFs) Armed Forces 
Institute of Pathology criteria for risk assessment.[2,5,6]
Majority (85%) of GISTs have mutations in the gene 
encoding the transmembrane tyrosine kinase receptor 
(KIT). Most GISTs which lack KIT mutations are wild-
type (approximately 10%) or harbour mutations in 
platelet-derived growth factor receptor which is highly 
homologous with KIT. NF1-associated GISTs usually 
retain expression of succinate dehydrogenase.[4]
Majority (about 80%) of gastric GISTs have low risk for 
malignancy. Duodenal GISTs are most often found in the 
second part of duodenum and about half of them have 
high risk for malignancy. GISTs of colon, anorectum, 
oesophagus, omentum and peritoneum represent a small 
percentage of all GISTs. Therefore, less is known about 
their biologic behaviour.[2,7,8]
While evaluating excision specimen of GIST, clinical 
history and any neoadjuvant treatment details are essential. 
Prior morphological appearance (spindle vs. epithelioid) 
and CD117 expression should also be known, as this 
information may change treatment.[2,7,9]
Materials and Methods
A total of 31 patients who underwent excision of GIST 
from January 2009 to January 2015, at Shifa International 
Hospital were evaluated, after approval from the 
institution research board and ethical committee. Cases 
were included, irrespective of age, gender and with or 
without neoadjuvant chemotherapy administration.
The data were analysed by SPSS 17. Mean ± standard 
deviation (SD) of quantitative variables like age was 
calculated. Frequency and percentage for variables 
such as gender, tumour site, tumour size, mitotic count, 
morphologic pattern, necrosis and risk categorisation 
were determined. IHC pattern of CD117, DOG1, 
ASMA, CKAE1/AE3 and S100, resection margin status, 
neoadjuvant chemotherapy administration and its effects 
were noted.
Results
Of 31 patients, 21 (67.7%) were male and 10 (32.3%) were 
female with male-to-female ratio of 2.1:1. Distribution 
according to the location of tumour was as follows: Gastric 
13 (41.9%), extra visceral 6 (19.4%), small intestine 
9 (29.0%), rectum 2 (6.5%) and pancreas 1 (3.2%). In 
cases of small intestine, jejunum/ileum was the site in 
3 (9.7%) and duodenum in 2 (6.5%), while in 4 (12.9%) 
exact site in small intestine was not specified.
Tumour was <5 cm in 6 cases (19.4%), >5 cm but 
<10 cm in 12 cases (38.7%) and >10 cm in 13 (41.9%) 
cases. Mitotic figures per 50 HPF were ≤5 in 11 cases 
(35.5%) and >5 in 20 cases (64.5%). According to risk 
categorisation, 1 was (3.2%) very low risk, 3 (9.7%) low 
risk, 5 (16.1%) intermediate risk and 22 (71%) high risk 
[Table 1].
Of 31 cases, 21 (67.7%) had spindle cell morphology, 
7 (22.58%) had epithelioid appearance and 2 (6%) had 
mixed morphology. Necrosis was present in 48.4% 
(n = 15). Tumour was unifocal in 30 (96.8%) cases and 
multifocal in 1 (3.2%) cases. 16 (51.6%) had free resection 
margins.
CD117 was performed in 30 cases, of which 29 (93.5%) 
were positive and equivocal in 1 (3.2%). DOG1 was 
performed in 16 cases, of them 15 (48.4%) were positive 
and 1 (3.2%) was negative [Figure 1]. CD34 was 
performed in 22 cases, of which 17 (54.8%) were positive, 
while negative in 5 (16.1%).
ASMA was performed in 16 cases, of which 7 (22.6%) 
were positive and 9 (29%) were negative. S100 was 
performed in 13 cases, of which 3 (9.7%) were positive 
and 10 (32.3%) were negative. CKAE1/AE3 was 
performed in only four cases, and all were negative. 
Desmin was performed in one case, which was negative.
Neoadjuvant chemotherapy was given in 11 cases 
(35.5%). The mean duration of post-surgical follow-
up was 30 months (range 4–59 months). Follow-up 
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was available in 21 patients. 7 patients (22.5%) lost to 
follow-up. 8 (25%) had recurrence and 4 (12.9%) died.
Discussion
DeMatteo et al. reported GIST distribution to be 54% in 
stomach, 16% in rectum and 15% in small intestine.[1,10] 
In DeMatteo et al. study, less than one-third of tumours 
were ≤5 cm. >2/3rd of our tumours, i.e., 80.6% were >5 cm 
in greatest tumour dimension. Postsurgically, negative 
margins were reported in 81% of cases.[10] While we 
had negative resection margins in 51.6%, probably due 
to large proportion of high-risk category GIST in our 
study. Follow-up in this study had a median follow-up of 
24 months and documented disease-specific survival in 
69% at 1 year. 46% were alive, 29% free of disease, 50% 
died of disease and 33% had isolated local recurrence.[10]
Zhao et al., 70% of cases had spindle cell morphology 
and 20–25% had epithelioid while rest of cases had mixed 
appearance. Up to 95% of them are positive for CD117. 
GISTs can be negative or minimally positive for CD 117 
in <5% of cases.[6] We had 58.1% of cases of spindle cell 
Table 1: Characteristics and risk stratification of patients
No Age (years) Gender Site Morphological pattern  Risk stratification 
1 59 Male Small intestine Spindle cell High risk 
2 70 Male Extra visceral Spindle cell High risk 
3 69 Male Stomach Epithelioid High risk 
4 40 Female Rectum Epithelioid High risk 
5 45 Male Extra visceral Spindle cell High risk 
6 62 Male Extra visceral Spindle cell High risk 
7 55 Female Extra visceral Spindle cell High risk 
8 57 Male Stomach Epithelioid Intermediate risk 
9 63 Male Jejunum/ileum Mixed High risk 
10 23 Female Stomach Epithelioid Intermediate risk 
11 53 Male Stomach Spindle cell High risk 
12 65 Male Stomach Spindle cell Very low risk 
13 68 Male Extra visceral Epithelioid High risk 
14 68 Male Stomach Spindle cell Low risk 
15 48 Male Stomach Spindle cell Low risk 
16 20 Female Extra visceral Spindle cell Intermediate risk 
17 72 Male Jejunum Spindle cell High risk 
18 Female Stomach Spindle cell High risk 
19 49 Male Small intestine Spindle cell Intermediate risk 
20 67 Female Stomach Spindle cell Low risk 
21 58 Female Jejunum Spindle cell High risk 
22 43 Male Duodenum Epithelioid High risk 
23 45 Female Stomach Spindle cell Intermediate risk 
24 41 Male Small intestine Epithelioid High risk 
25 45 Male Stomach Spindle cell High risk 
26 47 Female Stomach Spindle cell High risk 
27 51 Male Small intestine Spindle cell High risk 
28 54 Male Rectum Mixed High risk 
29 62 Female Pancreas Spindle cell High risk 
30 48 Male Stomach Spindle cell High risk 
31 43 Male Duodenum Spindle cell High risk 
JOURNAL OF CANCER & ALLIED SPECIALTIES 4
ORIGINAL ARTICLE J Cancer Allied Spec 2016;2(4):3
morphology, 6.5% with epithelioid appearance and 6.5% 
had mixed morphology. The variation is likely due to non-
documentation of morphological appearance in nine cases 
which make up to 29.9% of them. CD117 was positive in 
93.5% and equivocal in 3.2%.
Miettinen et al. analysed 13 omental and 10 mesenteric 
GISTs with spindle cells or epithelioid cells; most of 
these tumours showed low mitotic activity.[11,12] Reith 
et al. had analysed 48 GISTs of abdominal soft tissues, 
with the range of morphological features including purely 
epithelioid cells to those composed of spindle morphology 
as well some cases exhibiting mixed pattern. We had 
six extra-visceral cases, with four of them exhibiting 
spindle cell morphology while in two cases, pattern was 
not documented. Miettinen et al. had documented that 
omental and mesenteric GISTs were typically positive 
for CD117.[12] Reith et al. tumours expressed CD117 in 
100%.[13] <5% of extraintestinal GIST are negative for 
CD117.[14] All of our six cases were positive for CD117.
Data regarding survival of patients with adjuvant Imatinib 
therapy are limited. The median follow-up period was 
54 months with observation that 92% of patients receiving 
36 months of therapy were alive as compared to 82% 
alive for patients receiving 12 months. In recent larger 
institutional studies, a significant portion of GISTs had 
low to very low-risk chance of recurrence.[15-17]
Mucciarini et al. studied 124 GIST cases including 47% of 
high-risk cases. They observed 5-year disease-free survival 
rates after complete resection was 94%, 92%, 100% and 
40% for patients at very low, low, intermediate and high 
risk, respectively.[3] Of 31 analysed cases in our study, 71% 
GISTs were of high-risk category, 16.1% in intermediate 
risk and 9.7% in very low risk while 3.2% had very low 
risk. 21 patients (67.7%) lost follow-up. 7 patients (22.5%) 
are asymptomatic, 1 (3.2%) had recurrence and 2 (6.5%) 
died. One (3.2%) of the asymptomatic patient received 
no further treatment after surgery. Patients who died and 
the one who had recurrence had GIST of high-risk group.
Surgical management of GISTs has been considered the 
most effective therapy. For locally advanced and metastatic 
GIST, Imatinib has been initiated.[17-20] DeMatteo et al. 
concluded that although complete resection is associated 
with good outcome, it is not sufficient treatment. It had 
been observed that complete resection of GIST with 
adjacent organs, if required, should be performed.[10]
Conclusion
Majority of cases diagnosed at our centre were gastric 
in origin followed by small intestine, and as per risk 
categorisation, most were high risk. Patient survival with 
high-risk tumours was dismal.
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